Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the
development of medical imaging software solutions that help medical
practitioners in better understanding lesions and critical anatomy,
congratulates the research team led by Francis J. Porreca, MD, FACS, RVPI,
Director of Vascular Surgery, Weiler Division of Montefiore Medical Center and
The University Hospital of the Albert Einstein College of Medicine, and
co-authors Angela Rodriguez-Wong, MD, RVT, RVPI and Joseph P. Hughes RVT, RVS
both of Navix Diagnostix, Inc. on their paper entitled "Three Dimensional
Reconstruction of the Vessel Lumen as an Adjunct to the Cerebrovascular Duplex
Evaluation" which was presented Thursday in Chicago at the Annual Vascular
Meeting. The Annual Vascular Meeting is a joint meeting for the Society for
Vascular Surgeons (SVS) and the Society for Vascular Ultrasound (SVU) and is
generally regarded as an important forum for discussing leading edge techniques
and technologies that advance vascular practice. The paper compared Color Flow
Doppler Ultrasound (CFDU) to standard 2D grayscale ultrasound using
Visualize:Vascular(TM) to render 3D visualization of carotid arteries. 


"In today's market where new technologies seem to come and go very quickly, it's
exciting to be part of a technology that will aide in the care of patients with
vascular disease and has the potential to have a positive impact on patient
care," commented Dr. Porreca.


Current standard practice uses Doppler ultrasound to measure the velocity of the
flow of blood through the carotid artery, where Stenosis (blockage and narrowing
of the carotid artery) is inferred based upon the measurements.
Visualize:Vascular segments the lumen (the active pathway for blood to flow
within an artery) and then reconstructs the lumen in 3D providing an interactive
view of the active pathway for the blood. The measurements within
Visualize:Vascular are derived from the 2D frames captured using an image
acquisition protocol which enables the 3D rendering and provides either
diameters or cross sectional areas at the minimum and maximum points in the
lumen.


The paper finds that 3D reconstruction technology using Visualize:Vascular
produced a statistically significant correlation between the two techniques
which can be used to calculate the reduction in the lumen. The team compared
luminal reduction as calculated by Visualize:Vascular with Stenosis as inferred
from velocity measurements. There was 99% (n=79, p = less than 0.001)
correlation between velocity estimates and 3D visualization for estimating
diameter reduction. Correlation for cases with less than 50% diameter reduction
by duplex was 100% (n = 66, p = less than 0.004), while correlation for cases
with 50% or greater diameter reduction by duplex was 92% (n = 13, p =less than 
0.03). While more investigation with a larger group of patients is necessary, 3D
reconstruction may be a valuable adjunct and may enhance the diagnostic
capabilities of Color Flow Doppler Ultrasound (CFDU) the paper concludes.


"Medipattern congratulates the team for this fine work," commented Jeff Collins,
President and CEO of The Medipattern Corporation. "The paper shows that
Visualize:Vascular is a very credible technology because it correlates closely
to the industry standard used most commonly for finding Stenosis today. The
research team believes that the luminal reduction values calculated by
Visualize:Vascular, along with the ability to view the lumen in 3D, provides
meaningful insight into the health of the artery for these patients. We look
forward to continuing to work with Dr. Porreca's group to continue to find
additional applications for this technology." 


2011 Upcoming Events:



--  Society of Vascular Surgery (SVS) Annual Meeting, Chicago June 16- 18 
--  Society of Vascular Ultrasound (SVU) Annual Meeting, Chicago June 16-18 



About The Medipattern Corporation:

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


B-CAD(R) and Medipattern(R) are a registered mark of The Medipattern Corporation. 

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more The Medipattern Corp. Charts.
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more The Medipattern Corp. Charts.